Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ERAP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERAP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERAP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERAP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERAP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
GO:00454449 | Esophagus | ESCC | fat cell differentiation | 135/8552 | 229/18723 | 3.38e-05 | 2.78e-04 | 135 |
GO:004800220 | Esophagus | ESCC | antigen processing and presentation of peptide antigen | 44/8552 | 62/18723 | 4.81e-05 | 3.78e-04 | 44 |
GO:001988225 | Esophagus | ESCC | antigen processing and presentation | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
GO:000247418 | Esophagus | ESCC | antigen processing and presentation of peptide antigen via MHC class I | 22/8552 | 28/18723 | 3.95e-04 | 2.26e-03 | 22 |
GO:00065095 | Esophagus | ESCC | membrane protein ectodomain proteolysis | 31/8552 | 43/18723 | 4.04e-04 | 2.30e-03 | 31 |
GO:00336195 | Esophagus | ESCC | membrane protein proteolysis | 39/8552 | 57/18723 | 4.34e-04 | 2.44e-03 | 39 |
GO:000248325 | Esophagus | ESCC | antigen processing and presentation of endogenous peptide antigen | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
GO:001988519 | Esophagus | ESCC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 14/8552 | 17/18723 | 2.22e-03 | 9.78e-03 | 14 |
GO:0019883111 | Esophagus | ESCC | antigen processing and presentation of endogenous antigen | 18/8552 | 26/18723 | 1.32e-02 | 4.31e-02 | 18 |
GO:00336192 | Liver | Cirrhotic | membrane protein proteolysis | 31/4634 | 57/18723 | 1.55e-06 | 3.02e-05 | 31 |
GO:00065092 | Liver | Cirrhotic | membrane protein ectodomain proteolysis | 24/4634 | 43/18723 | 1.30e-05 | 1.82e-04 | 24 |
GO:00198827 | Liver | Cirrhotic | antigen processing and presentation | 44/4634 | 106/18723 | 1.07e-04 | 1.10e-03 | 44 |
GO:00480027 | Liver | Cirrhotic | antigen processing and presentation of peptide antigen | 29/4634 | 62/18723 | 1.34e-04 | 1.31e-03 | 29 |
GO:00024837 | Liver | Cirrhotic | antigen processing and presentation of endogenous peptide antigen | 12/4634 | 19/18723 | 4.35e-04 | 3.55e-03 | 12 |
GO:00024747 | Liver | Cirrhotic | antigen processing and presentation of peptide antigen via MHC class I | 15/4634 | 28/18723 | 9.91e-04 | 6.98e-03 | 15 |
GO:001988512 | Liver | Cirrhotic | antigen processing and presentation of endogenous peptide antigen via MHC class I | 10/4634 | 17/18723 | 2.85e-03 | 1.64e-02 | 10 |
GO:00198837 | Liver | Cirrhotic | antigen processing and presentation of endogenous antigen | 13/4634 | 26/18723 | 4.72e-03 | 2.48e-02 | 13 |
GO:00028311 | Liver | Cirrhotic | regulation of response to biotic stimulus | 101/4634 | 327/18723 | 6.58e-03 | 3.25e-02 | 101 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERAP1 | SNV | Missense_Mutation | novel | c.2045N>A | p.Pro682His | p.P682H | Q9NZ08 | protein_coding | tolerated(0.56) | benign(0.094) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.1433N>A | p.Leu478Gln | p.L478Q | Q9NZ08 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ERAP1 | SNV | Missense_Mutation | rs372808514 | c.2836N>A | p.Ala946Thr | p.A946T | Q9NZ08 | protein_coding | | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.2135N>T | p.Asp712Val | p.D712V | Q9NZ08 | protein_coding | deleterious(0) | possibly_damaging(0.55) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.1614N>T | p.Arg538Ser | p.R538S | Q9NZ08 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.2579N>G | p.Leu860Arg | p.L860R | Q9NZ08 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.2519G>A | p.Gly840Asp | p.G840D | Q9NZ08 | protein_coding | deleterious(0.02) | probably_damaging(0.958) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.2210T>C | p.Val737Ala | p.V737A | Q9NZ08 | protein_coding | tolerated(0.55) | benign(0.031) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | novel | c.1240N>C | p.Asn414His | p.N414H | Q9NZ08 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP1 | SNV | Missense_Mutation | | c.777G>T | p.Lys259Asn | p.K259N | Q9NZ08 | protein_coding | tolerated(0.1) | benign(0.326) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | | TCMDC-124377 | CHEMBL531269 | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | 252166866 | | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | | UMBELLIFERONE | UMBELLIFERONE | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | | TCMDC-124673 | CHEMBL587247 | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | 348353641 | | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | 348353642 | | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | | SCOPOLETIN | SCOPOLETIN | |
51752 | ERAP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | | ESCULETIN | ESCULETIN | |